Lucid Diagnostics Inc (LUCD) Stock Price, Quote & News

Company Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths th...

Industry: Medical Devices

Sector: Healthcare

Phone: 917 813 1828

Website: www.luciddx.com

Address:

360 Madison Avenue, 25th Floor, New York, United States

oaksapollo Sep. 16 at 8:30 PM

$LUCD I know I'm sounding like a broken record here, but never before have I seen a $30B TAM, with a single company in the space, and a product backed by every KOL in the field (that I'm aware of) and the professional society guidelines. And if that weren't enough, the product prevents cancer. Not extends life by 3 months, not causes a partial response - PREVENTS ENTIRELY (as nicely demonstrated in the pub I posted early today). To paraphrase Dr. Shaheen at the CAC - it's a fundamental change in how patients are managed. The risk/reward here is absolutely, positively, without any shadow of a doubt, the best I've seen in 20+ years of investing in early stage biotech companies. There is no phase 3 read out, no FDA vote. It's like getting the potential for GLP1-type revenues with the risk profile of CVS. Can't wait to see where this goes over the next few years.

1 · Reply

DrKyle Sep. 16 at 8:30 PM

$LUCD a penny a day is $252K a year for many in here...I'll take it

0 · Reply

BlameTheBartender Sep. 16 at 8:15 PM

$LUCD "Lucid's strategic hire of reimbursement veteran Scelfo signals Medicare approval for EsoGuard is likely imminent, potentially transforming commercialization prospects". Stock Titan article...

0 · Reply

BioTuesdays Sep. 16 at 7:05 PM

$LUCD announced the appointment of Danielle Scelfo as SVP, Market Access & Government Affairs, reporting to the CEO https://biotuesdays.com/2025/09/16/lucid-appoints-policy-leader-danielle-scelfo-as-svp-market-access-govt-affairs/

0 · Reply

Elomee Sep. 16 at 3:27 PM

$LUCD "Ms. Scelfo most recently served as Vice President, Market Access & Health Policy at ClearNote Health, a commercial-stage cancer detection company focused on blood-based molecular tests. She previously held various senior market access, reimbursement, and health policy roles in the diagnostics sector, including leadership positions at CareDx, Inc., Hologic, Inc., Adaptive Biotechnologies Corporation, and Genomic Health, Inc. (now part of Exact Sciences, Inc.)" I like how they snuck in a connection to Exact. for the people who think there is an Exact acquisition in the future, this must feed their theories.

1 · Reply

oaksapollo Sep. 16 at 2:52 PM

$LUCD new pub https://www.gastroenterologyandhepatology.net/archives/september-2025/barrett-high-grade-dysplasia-and-early-esophageal-adenocarcinoma-in-patients-with-positive-results-on-a-nonendoscopic-methylated-dna-biomarker-test/ Four lives saved via a positive EsoGuard test, that otherwise would have received a death sentence diagnosis of esophageal cancer when it is too late. This test is a game changer.

1 · Reply

Crookedeye Sep. 16 at 1:47 PM

$LUCD So what does that mean more salaries to pay?

1 · Reply

tds_ Sep. 16 at 12:04 PM

$LUCD Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs https://ir.luciddx.com/2025-09-16-Lucid-Diagnostics-Appoints-Danielle-Scelfo-as-Senior-Vice-President,-Market-Access-Government-Affairs

2 · Reply

Lets_Go_Brndn Sep. 15 at 8:11 PM

$LUCD Good day today. 1 week at a time - month by month. Not as many shares as many on here- but if my biggest position does what I think it will in a few weeks/months- I will be one of the biggest retail holders here as I plan to sink 100% of that position right here. Until they are bought- this is a good entry at any price.

0 · Reply

BlameTheBartender Sep. 15 at 6:43 PM

$LUCD Crain's article today also suggests Medicare coverage as well coming soon. Besides Medicare, additional insurance coverages for those under 65 would add a large market for our tests. I hope the additional cash raised is allowing us to market in the EU as well now. So many potential markers-pretty exciting times for us. We can't rule out being acquired by a larger Pharma either..

4 · Reply

Market Cap	111.73M
Revenue (ttm)	4.35M
Net Income (ttm)	-45.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,046.67%
Debt to Equity Ratio	3.22

Volume	1,506,009
Avg Vol	1,157,482
Day's Range	N/A - N/A
Shares Out	108.48M
Stochastic %K	9%
Beta	1.24
Analysts	Strong Sell
Price Target	$3.71